Searched over 200M research papers
7 papers analyzed
Some studies suggest that discontinuing metformin can lead to the loss of its beneficial effects on weight and metabolic abnormalities, while other studies indicate it may be necessary to stop metformin before surgery to prevent complications like lactic acidosis.
19 papers analyzed
Metformin is a widely prescribed medication for managing type 2 diabetes mellitus (T2DM). It helps control blood sugar levels and has additional benefits such as improving lipid profiles and reducing microvascular and macrovascular complications. However, patients and healthcare providers often face the dilemma of whether to discontinue metformin, especially in the presence of certain health conditions or before surgical procedures.
Discontinuing metformin can lead to significant changes in glycemic control and body weight. Studies have shown that patients who stop taking metformin experience a rise in body mass index (BMI) and hemoglobin A1c levels, indicating poorer blood sugar control compared to those who continue the medication. Additionally, the beneficial effects of metformin on body weight and metabolic traits in patients with schizophrenia were found to disappear after discontinuation.
In the Diabetes Prevention Program (DPP), metformin significantly reduced the risk of developing diabetes in individuals with impaired glucose tolerance. However, after a short "washout" period where metformin was discontinued, the incidence of diabetes increased, suggesting that part of metformin's protective effect is pharmacological and does not persist after stopping the drug.
Traditional guidelines contraindicate the use of metformin in patients with renal impairment due to the risk of lactic acidosis. However, recent studies suggest that metformin can be safely continued in patients with mild to moderate renal insufficiency, as well as those with coronary heart disease (CHD), congestive heart failure (CHF), and chronic obstructive pulmonary disease (COPD), without increasing the risk of lactic acidosis .
Metformin should be discontinued 48 hours before surgery to reduce the risk of lactic acidosis, a serious perioperative complication. This precaution is particularly important in patients undergoing general anesthesia.
Metformin's effects extend beyond glucose reduction, involving gut-based mechanisms such as altering bile acid recirculation and gut microbiota. Withdrawal of metformin leads to changes in gut hormones and bile acids, which reverse upon restarting the medication. These findings highlight the complex pharmacology of metformin and its broader metabolic effects.
Stopping metformin can lead to poorer glycemic control, weight gain, and an increased risk of developing diabetes. While it is generally safe to continue metformin in patients with mild to moderate renal impairment and certain cardiovascular conditions, it should be discontinued before surgery to prevent lactic acidosis. The decision to stop metformin should be carefully considered and discussed with a healthcare provider, taking into account the individual patient's health status and the potential risks and benefits.
Most relevant research papers on this topic